Provexis PLC Result of AGM (3968L)
01 October 2016 - 12:33AM
UK Regulatory
TIDMPXS
RNS Number : 3968L
Provexis PLC
30 September 2016
30 September 2016
Provexis plc
Result of AGM
Provexis plc (the "Company") is pleased to announce that at the
Annual General Meeting of the Company held today all the
resolutions were duly passed.
- ends -
For further information please contact:
Provexis plc Tel: 07490 391888
Ian Ford, Finance Director enquiries@provexis.com
Cenkos Securities plc Tel: 020 7397 8900
Bobbie Hilliam
Notes for editors
About Provexis plc
AIM-listed Provexis is focused on the development and licensing
of its proprietary, scientifically-proven Fruitflow(R) heart-health
functional food ingredient.
In May 2009, the Company's Fruitflow(R) technology was the first
to be substantiated by the European Food Safety Authority ("EFSA")
under the new Article 13(5) for proprietary and emerging science.
In December 2009 the European Commission authorised the health
claim "Helps maintain normal platelet aggregation, which
contributes to healthy blood flow", which was the first wording to
be authorised under Article 13(5).
In June 2010 it was announced that the Company had entered into
a long-term Alliance Agreement with DSM Nutritional Products to
commercialise Fruitflow(R), and in June 2015 the Company confirmed
it had agreed significantly enhanced financial terms for its
Alliance Agreement with DSM for Fruitflow(R).
The Company's Alliance partner DSM Nutritional Products has
developed the market actively for the Company's novel, patented
Fruitflow(R) heart-health ingredient in all global markets, with
over 50 regional consumer healthcare brands now having been
launched by direct customers of DSM, and with a number of further
regional brands having been launched through DSM's distributor
channels.
An increasing number of further commercial projects have been
initiated by DSM with prospective customers, including some
prospective customers which are part of global businesses, with
good prospects for these projects to be launched as consumer
products. Interest in the technology exists in all major global
markets.
On 29 June 2016 the Company launched a high quality dietary
supplement product containing Fruitflow(R) and Omega-3 which is
being sold initially from a separate, dedicated website
www.fruitflowplus.com on a mail order basis.
The Company conducted a Key Opinion Leaders' roundtable event
for Fruitflow(R) in London on 29 September 2016, focussed on
raising awareness of the importance of blood flow in cardiovascular
health, and the effectiveness of dietary antiplatelets. The
roundtable was attended by key scientists from Provexis and DSM,
along with a number of interested health care professionals with
close links to the media. The event was recorded with a view to
producing two further promotional videos: a video for Fruitflow(R)
targeting prospective trade customers, and a video for Fruitflow(R)
+ Omega-3 capsules targeting prospective consumers.
Video content recorded at the event and subsequently will be
used to promote Fruitflow(R) and the Company's Fruitflow(R) +
Omega-3 capsules more widely across key digital and other
mainstream media channels.
The Company and DSM are keen to secure greater medical advocacy
for Fruitflow(R) and the roundtable event forms part of this
strategy. The roundtable event will also be supported by a broader
consumer PR campaign.
The Company is engaged in a two stage collaboration agreement
with the University of Oslo ('the University') to undertake further
research into the relationship between Fruitflow(R) and blood
pressure regulation. The Company is very pleased with the
encouraging results from the first stage of the collaboration with
strong evidence that a standard dose of Fruitflow(R) has the
potential to give a clinically relevant reduction in systolic blood
pressure. The Company and the University expect to be able to
complete a small clinical trial by way of a proof of principle
study in Q4 2016 and the results of the proof of principle study
will be announced as soon as possible thereafter.
Provexis was founded in 1999 and is headquartered in Reading,
Berkshire.
Provexis shares are traded on the AIM market of the London Stock
Exchange under the ticker symbol PXS.
For further information, please visit www.provexis.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGZBLFXQKFXBBF
(END) Dow Jones Newswires
September 30, 2016 10:33 ET (14:33 GMT)
Provexis (LSE:PXS)
Historical Stock Chart
From Apr 2024 to May 2024
Provexis (LSE:PXS)
Historical Stock Chart
From May 2023 to May 2024